home / stock / akca / akca news

AKCA News and Press, Akcea Therapeutics Inc. From 08/31/20

Stock Information
Company Name: Akcea Therapeutics Inc.
Stock Symbol: AKCA
Market: NASDAQ
Website: akceatx.com
Menu
AKCA AKCA Quote AKCA Short AKCA News AKCA Articles AKCA Message Board
Get AKCA Alerts

News, Short Squeeze, Breakout and More Instantly...
AKCA - AMRN, DVAX among premarket gainers

Aimmune Therapeutics (NASDAQ: AIMT ) +171%  on being acquired by Nestle. More news on: Aimmune Therapeutics, Inc., Akcea Therapeutics, Inc., Genworth Financial, Inc., , , Read more ...

AKCA - Ionis Pharmaceuticals to acquire remaining stake in Akcea Therapeutics

CARLSBAD, Calif. and BOSTON , Aug. 31, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and its affiliate Akcea Therapeutics, Inc. (NASDAQ: AKCA) today announced that they have entered into a definitive agreement under which Ionis will acquire all of the outstanding ...

AKCA - Positive Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L(Rx)) Presented at ESC Congress 2020

BOSTON and CARLSBAD, Calif. , Aug. 29, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data from the Phase 2 clinical trial of vupanorsen (AKCEA-ANGPTL3-L R...

AKCA - Positive Phase 2 Clinical Data of AKCEA-APOCIII-L(Rx) Presented at ESC Congress 2020

BOSTON and CARLSBAD, Calif. , Aug. 29, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), presented data today from the Phase 2 study of AKCEA-APOCIII-L Rx i...
AKCA - Akcea and Ionis to Present Phase 2 Clinical Data of Vupanorsen (AKCEA-ANGPTL3-L (Rx) ) at ESC Congress 2020

BOSTON and CARLSBAD, Calif. , Aug. 24, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 clinical trial of vupanorsen (AKC...

AKCA - Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020

BOSTON and CARLSBAD, Calif. , Aug. 18, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that data from the Phase 2 study of AKCEA-APOCIII-L Rx wi...

AKCA - Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany

BOSTON , Aug. 13, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., today announced that the German Association of Statutory Sick Funds has agreed upon new pricing and reimbursement of WAYLIVRA ® (volanesors...
AKCA - Akcea Therapeutics, Inc. 2020 Q2 - Results - Earnings Call Presentation

The following slide deck was published by Akcea Therapeutics, Inc. in conjunction with their 2020 Q2 earnings Read more ...

AKCA - Akcea Therapeutics, Inc. (AKCA) Q2 2020 Earnings Call Transcript

Image source: The Motley Fool. Akcea Therapeutics, Inc.   (NASDAQ: AKCA) Q2 2020 Earnings Call Aug 4, 2020 , 4:30 p.m. ET Operator Continue reading

AKCA - Akcea Therapeutics, Inc. (AKCA) CEO Damien McDevitt on Q2 2020 Results - Earnings Call Transcript

Akcea Therapeutics, Inc. (AKCA) Q2 2020 Earnings Conference Call August 4, 2020 16:30 ET Company Participants Angelyn Lowe - Executive Director, Corporate Communications & Investor Relations Damien McDevitt - Director & Chief Executive Officer Kyle Jenne - Chief Commercia...
Previous 10 Next 10